Salivary Duct Carcinoma

  • Joaquín J. García


Salivary duct carcinoma affects primarily adults and presents at a mean age of approximately 60 years. Women are involved less than men. The majority of cases involve the parotid gland, presenting as single or multiple masses. Most cases of salivary duct carcinoma behave as high-grade malignancies. Salivary duct carcinoma is infiltrative, comprised almost exclusively of one cell type (ductal), and exhibit a variety of architectural patterns (solid, trabecular, cribriform, and microcystic) (Figs. 25.1, 25.2, 25.3, 25.4, 25.5, 25.6, 25.7, 25.8, 25.9, 25.10, 25.11, 25.12, 25.13, 25.14, 25.15, 25.16, 25.17, 25.18, 25.19, 25.20, 25.21, 25.22, 25.23, 25.24, 25.25 and 25.26).


Cribriform carcinoma Cribriform salivary carcinoma of excretory ducts High-grade salivary duct carcinoma 

Suggested Reading

  1. Salivary duct carcinoma in major and minor salivary glands. J Craniomaxillofac Surg. 1989;17(8):373.Google Scholar
  2. Barnes L, Rao U, Contis L, Krause J, Schwartz A, Scalamogna P. Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol. 1994a;78(1):74–80.CrossRefGoogle Scholar
  3. Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol. 1994b;78(1):64–73.CrossRefGoogle Scholar
  4. Brandwein MS, Jagirdar J, Patil J, Biller H, Kaneko M. Salivary duct carcinoma (cribriform salivary carcinoma of excretory ducts). A clinicopathologic and immunohistochemical study of 12 cases. Cancer. 1990;65(10):2307–14.CrossRefGoogle Scholar
  5. Delgado R, Vuitch F, Albores-Saavedra J. Salivary duct carcinoma. Cancer. 1993;72(5):1503–12.CrossRefGoogle Scholar
  6. Etges A, Pinto DS Jr, Kowalski LP, Soares FA, Araujo VC. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol. 2003;56(12):914–8.CrossRefGoogle Scholar
  7. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000;24(4):579–86.CrossRefGoogle Scholar
  8. Fan CY, Melhem MF, Hosal AS, Grandis JR, Barnes EL. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg. 2001;127(9):1075–9.CrossRefGoogle Scholar
  9. Fayemi AO, Toker C. Salivary duct carcinoma. Arch Otolaryngol. 1974;99(5):366–8.CrossRefGoogle Scholar
  10. Garland TA, Innes DJ Jr, Fechner RE. Salivary duct carcinoma: an analysis of four cases with review of literature. Am J Clin Pathol. 1984;81(4):436–41.CrossRefGoogle Scholar
  11. Henley JD, Seo IS, Dayan D, Gnepp DR. Sarcomatoid salivary duct carcinoma of the parotid gland. Hum Pathol. 2000;31:208–13.CrossRefGoogle Scholar
  12. Jaehne M, Dippel A, Sagowski C. Salivary duct carcinoma of the submandibular gland. HNO. 2005a;53(11):940–4.CrossRefGoogle Scholar
  13. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 2005b;103(12):2526–33.CrossRefGoogle Scholar
  14. Jayaprakash V, Merizanu M, Warren GW, Arshad H, Hicks WL Jr, Rigual NR, et al. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the surveillance, epidemiology, and end results database. Head Neck. 2014;36:694–701.CrossRefGoogle Scholar
  15. Kusafuka K, Onitsuka T, Muramatsu K, Miki T, Murai C, Suda T, et al. Salivary duct carcinoma with rhabdoid features: report of 2 cases with immunohistochemical and ultrastructural analyses. Head Neck. 2014;36:E28–35.CrossRefGoogle Scholar
  16. Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996;77(2):223–30.CrossRefGoogle Scholar
  17. Martinez-Barba E, Cortes-Guardiola JA, Minguela-Puras A, Torroba-Caron A, Mendez-Trujillo S, Bermejo-Lopez J. Salivary duct carcinoma: clinicopathological and immunohistochemical studies. J Craniomaxillofac Surg. 1997;25(6):328–34.CrossRefGoogle Scholar
  18. Masubuchi T, Tada Y, Maruya SI, Osamura Y, Kamata SE, Miura K, et al. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol. 2015;20(1):35–44.CrossRefGoogle Scholar
  19. Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer. 2001;93(5):344–50.CrossRefGoogle Scholar
  20. Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck. 2007;29(10):907–12.CrossRefGoogle Scholar
  21. Nagao T, Gaffey TA, Visscher DW, Kay PA, Minato H, Serizawa H, et al. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance. Am J Surg Pathol. 2004;28(3):319–26.CrossRefGoogle Scholar
  22. Ponniah I, Murali GM, SureshKumar P, Kumaran MG, Shaheen A. Salivary duct carcinoma of the palate. Indian J Dent Res. 2005;16(4):167–70.CrossRefGoogle Scholar
  23. Roh JL, Cho KJ, Kwon GY, Choi SH, Nam SY, Kim SY. Prognostic values of pathologic findings and hypoxia markers in 21 patients with salivary duct carcinoma. J Surg Oncol. 2008;97(7):596–600.CrossRefGoogle Scholar
  24. Shimizu A, Yamane M, Ito H, Araki S, Yoshida T, Suzuki M. Clinicopathological study of salivary duct carcinoma. Nihon Jibiinkoka Gakkai Kaiho. 2002;105(6):727–31.CrossRefGoogle Scholar
  25. Simpson RH. Salivary duct carcinoma: new developments-morphological variants including pure in situ high-grade lesions: proposed molecular classification. Head Neck Pathol. 2013;7(Suppl 1):S48–58.CrossRefGoogle Scholar
  26. Simpson RHW, Desai S, Di Palma S. Salivary duct carcinoma in situ of the parotid gland. Histopathology. 2008;53(4):416–25.CrossRefGoogle Scholar
  27. Skalova A. Starek, Kucerova V, Szepe P, plank L. salivary duct carcinoma—a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract. 2001;197(9):621–6.CrossRefGoogle Scholar
  28. Skalova A, Starek I, Vanecek T, Kucerova V, Plank L, Szepe P. Amplification and overexpression of HER-2/neu in parotid gland salivary duct carcinoma. Immunohistochemical study and fluorescence in situ hybridization. Cesk Patol. 2002;38(Suppl 1):27–34.PubMedGoogle Scholar
  29. Williams L, Thompson LD, Seethala RR, Weinreb I, Assaad AM, Tuluc M, et al. Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression. Am J Surg Pathol. 2015;39:705–13.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Joaquín J. García
    • 1
  1. 1.Mayo Clinic School of Medicine, Department of Laboratory Medicine & PathologyMayo Clinic RochesterRochesterUSA

Personalised recommendations